CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseasesPRNewsWire • 10/04/26
Lancet Publication Marks Important Advance in Influenza Prevention for Older AdultsPRNewsWire • 09/10/26
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized DrugmakersZacks Investment Research • 09/01/26
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakersCNBC • 08/31/26
CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)PRNewsWire • 07/27/26
CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European UnionPRNewsWire • 06/26/26